Back to Search Start Over

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Authors :
Angelo Pan
Sumanth Gandra
Elena Carrara
Souha S. Kanj
Karin Leder
Yang Soo Kim
Ana Cristina Gales
Christopher R. Houchens
Babacar Ndoye
Haibo Qiu
Lynn L. Silver
Jesús Rodríguez-Baño
Jasper Littman
David L. Paterson
Oliver J. Dyar
Paul Hansen
Mical Paul
Neil Woodford
Pilar Ramon-Pardo
Marie-Paule Kieny
Nalini Singh
Massinissa Si-Mehand
Wonkeung Song
Fidan O Yilmaz
Thomas Gottlieb
Jean B. Patel
Aaron O. Aboderin
Nguyen Van Kinh
Marc Mendelson
Seif Al-Abri
Manuel Guzman Blanco
Agnes Wechsler-Fördös
Waleria Hryniewicz
Vikas Manchanda
Timothy Jinks
Evelyn Wesangula
Gunnar Kahlmeter
Nicola Magrini
Otto Cars
Mike Sharland
Lawrence Kerr
Jaime Labarca
Debra A. Goff
Ursula Theuretzbacher
Francesco Robert Burkert
Gabriel Levy-Hara
Deepthi Kattula
Jan Kluytmans
Edward Cox
Jens Thomsen
Surbhi Malhotra-Kumar
Alexander W. Friedrich
Marco Cavaleri
Nordiah Awang Jalil
Maria Virginia Villegas
Roman S. Kozlov
Guy E. Thwaites
Kevin Outterson
Leonard Leibovici
Jos W. M. van der Meer
Stéphan Juergen Harbarth
Silvio Vega
Yehuda Carmeli
Dominique L Monnet
Lorenzo Moja
Heiman F. L. Wertheim
Martin Steinbakk
Giuseppe Cornaglia
Ramanan Laxminarayan
Maurizio Sanguinetti
Adrian Brink
Nur Benzonana
Sanjay Bhattacharya
Anna Zorzet
Alessia Savoldi
Céline Pulcini
Christian G. Giske
Herman Goossens
Evelina Tacconelli
M Lindsay Grayson
Sharmila Sengupta
Marc Ouellette
University Hospital Tübingen
University Hospital of Verona
Geneva University Hospital (HUG)
University of Cape Town
European Centre for Disease Prevention and Control (ECDC)
Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC)
Université de Lorraine (UL)
Växjö Hospital
Laboratory for Microbiology and Infection Control
Amphia Hospital
University Medical Center [Utrecht]
Université Laval [Québec] (ULaval)
Boston University [Boston] (BU)
Centers for Disease Control and Prevention [Atlanta] (CDC)
Centers for Disease Control and Prevention
European Medicines Agency [London] (EMA)
U.S. Food and Drug Administration (FDA)
University of Melbourne
University of Otago [Dunedin, Nouvelle-Zélande]
The George Washington University (GW)
Center for Anti-Infective Agents
World Health Organization [Geneva]
WHO Pathogens Priority List Working Group
Source :
Lancet Infectious Diseases, 18, 3, pp. 318-327, The Lancet Infectious Diseases, The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2018, 18 (3), pp.318-327. ⟨10.1016/S1473-3099(17)30753-3⟩, The lancet infectious diseases, The Lancet Infectious Diseases, Vol. 18, No 3 (2018) pp. 318-327, Lancet Infectious Diseases, 18, 318-327
Publication Year :
2018

Abstract

Summary Background The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs. Methods We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated. The final priority ranking of the antibiotic-resistant bacteria was established after a preference-based survey was used to obtain expert weighting of criteria. Findings We selected 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority: mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline. We stratified the priority list into three tiers (critical, high, and medium priority), using the 33rd percentile of the bacterium's total scores as the cutoff. Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa , and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae. The highest ranked Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin-resistant Staphylococcus aureus . Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori , and fluoroquinolone-resistant Campylobacter spp, Neisseria gonorrhoeae , and Salmonella typhi were included in the high-priority tier. Interpretation Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria. The global strategy should include antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, N gonorrhoeae , and H pylori . Funding World Health Organization.

Details

ISSN :
14733099 and 14744457
Database :
OpenAIRE
Journal :
Lancet Infectious Diseases, 18, 3, pp. 318-327, The Lancet Infectious Diseases, The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2018, 18 (3), pp.318-327. ⟨10.1016/S1473-3099(17)30753-3⟩, The lancet infectious diseases, The Lancet Infectious Diseases, Vol. 18, No 3 (2018) pp. 318-327, Lancet Infectious Diseases, 18, 318-327
Accession number :
edsair.doi.dedup.....18dd52a4205d1deff62e1257cc93dcfd
Full Text :
https://doi.org/10.1016/S1473-3099(17)30753-3⟩